Consensus The Chemours Company

Equities

CC

US1638511089

Market Closed - Nyse 04:00:02 2024-03-18 pm EDT 5-day change 1st Jan Change
27.8 USD +2.43% Intraday chart for The Chemours Company +6.43% -11.86%

Evolution of the average Target Price on The Chemours Company

Price target over the last 5 years

History of analyst recommendation changes

54c6af7ce095be79ef82db87eb6a97e._iltEJHfXys_-Sos5uJHr87OcVCvWs-td7dVTZV_2Cg.j1gqRN2VFk1Oy3sViLEi_b-9AwPlNqjjT9gSfNY1gHyXfANGp-ZoU3iTTQ~a37c5415521f7585251dae1a2fd69407
UBS Downgrades Chemours to Neutral From Buy, Cuts Price Target to $21 From $37 MT
BMO Capital Downgrades Chemours to Underperform From Outperform, Adjusts Price Target to $19 From $45 MT
RBC Upgrades Chemours to Outperform From Sector Perform, Lifts Price Target to $40 From $28 on Titanium Technologies Recovery, Thermal & Specialized Solutions Strength MT
Goldman Sachs Adjusts Chemours' Price Target to $30 From $35, Maintains Neutral Rating MT
BMO Capital Adjusts Chemours' PT to $39 From $45, Keeps Outperform Rating MT
Morgan Stanley Cuts Price Target on Chemours to $28 From $33, Maintains Equal-Weight Rating MT
Barclays Cuts Price Target on Chemours to $28 From $31, Maintains Equal-Weight Rating MT
RBC Cuts Price Target on Chemours to $28 From $30, Keeps Sector Perform Rating MT
UBS Cuts Chemours Price Target to $37 From $41, Maintains Buy Rating MT
RBC Cuts Price Target on Chemours to $30 From $40, Keeps Sector Perform Rating MT
BofA Securities Adjusts Price Target on Chemours to $32 From $39, Maintains Neutral Rating MT
UBS Cuts Chemours Price Target to $41 From $47, Maintains Buy Rating MT
Barclays Adjusts Price Target on Chemours to $31 From $40, Keeps Equalweight Rating MT
BMO Capital Adjusts Price Target on Chemours to $53 From $64, Maintains Outperform Rating MT
RBC Boosts Price Target on Chemours to $40 From $37, Maintains Sector Perform Rating MT
UBS Adjusts Chemours Price Target to $47 From $43, Maintains Buy Rating MT
Barclays Adjusts Price Target on Chemours Company to $40 From $38, Maintains Equalweight Rating MT
BofA Securities Downgrades Chemours to Neutral From Buy, Lowers Price Target to $37 From $41 MT
UBS Raises Chemours' Price Target to $43 From $41, Maintains Buy Rating MT
RBC Lifts Price Target on Chemours to $37 From $36 on Recent PFAS Settlement, Maintains Sector Perform Rating MT
BMO Capital Adjusts Chemours' Price Target to $64 From $54, Keeps Outperform Rating MT
JPMorgan Adjusts Price Target on Chemours to $30 From $35, Maintains Neutral Rating MT
BMO Capital Adjusts Price Target on Chemours to $54 From $52, Maintains Outperform Rating MT
RBC Lifts Price Target on Chemours to $36 From $35 on Q1 Beat, 'Intact' 2023 Guidance; Sector Perform Rating Kept MT
Credit Suisse Lowers Chemours' Price Target to $25 From $27, Keeps Underperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
27.8 USD
Average target price
29 USD
Spread / Average Target
+4.32%
High Price Target
40 USD
Spread / Highest target
+43.88%
Low Price Target
19 USD
Spread / Lowest Target
-31.65%

Consensus detail

Consensus revision (last 18 months)

Analysts covering The Chemours Company

UBS
BMO Capital
RBC Capital Markets
Goldman Sachs
Morgan Stanley
Barclays
BofA Securities
JPMorgan Chase
Credit Suisse
Citigroup
Argus
Alembic Global
Wolfe Research
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings